Literature DB >> 23856032

FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer.

Chao Yang1, Hui Chen, Guixiang Tan, Wei Gao, Liang Cheng, Xia Jiang, Li Yu, Yongjun Tan.   

Abstract

The Forkhead Box M1 (FOXM1) transcription factor is involved in tumorigenesis and tumor progression in multiple human carcinomas. In this study, we found that FOXM1 promoted the epithelial to mesenchymal transition (EMT) in human breast cancer. We observed a strong correlation between the expression levels of FOXM1 and the mesenchymal phenotype. Knockdown of FOXM1 inhibited the mesenchymal phenotype, whereas stable overexpression of FOXM1 induced EMT in breast cancer cells. FOXM1 was found to endogenously bind to and stimulate the promoter of Slug that is crucial for EMT progression. The knockdown of Slug abolished the EMT-inducing function of FOXM1. The stable overexpression of FOXM1 promoted metastasis of breast cancer cells in vivo. This study confirmed that FOXM1 promoted EMT in breast cancer cells by stimulating the transcription of EMT-related genes such as Slug.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; EMT; FOXM1 transcription factor; Slug Transcription

Mesh:

Substances:

Year:  2013        PMID: 23856032     DOI: 10.1016/j.canlet.2013.07.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  54 in total

1.  MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.

Authors:  Guoyan Liu; Yan Sun; Ping Ji; Xia Li; David Cogdell; Da Yang; Brittany C Parker Kerrigan; Ilya Shmulevich; Kexin Chen; Anil K Sood; Fengxia Xue; Wei Zhang
Journal:  J Pathol       Date:  2014-05-21       Impact factor: 7.996

2.  Tight correlation between FoxM1 and FoxP3+ Tregs in gastric cancer and their clinical significance.

Authors:  Xiaoxiao Li; Kai Ma; Shanai Song; Fangzhen Shen; Tao Kuang; Yingqian Zhu; Zimin Liu
Journal:  Clin Exp Med       Date:  2018-05-26       Impact factor: 3.984

Review 3.  Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors.

Authors:  Maria V Bogachek; James P De Andrade; Ronald J Weigel
Journal:  Cancer Res       Date:  2014-12-18       Impact factor: 12.701

4.  Resistance to HER2-targeted therapies: a potential role for FOXM1.

Authors:  Bridgette F Peake; Rita Nahta
Journal:  Breast Cancer Manag       Date:  2014

Review 5.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

Review 6.  Glioblastoma multiforme formation and EMT: role of FoxM1 transcription factor.

Authors:  Zhongyong Wang; Sicong Zhang; Timothy L Siu; Suyun Huang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  MicroRNA-370 directly targets FOXM1 to inhibit cell growth and metastasis in osteosarcoma cells.

Authors:  Ning Duan; Xiaojing Hu; Xiaowei Yang; Huiguang Cheng; Wentao Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth.

Authors:  T Chen; J Xiong; C Yang; L Shan; G Tan; L Yu; Y Tan
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

9.  Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition.

Authors:  Qingguo Li; Jitao Wu; Ping Wei; Ye Xu; Changhua Zhuo; Yuwei Wang; Dawei Li; Sanjun Cai
Journal:  Am J Cancer Res       Date:  2015-05-15       Impact factor: 6.166

10.  Quantitative proteomic analysis identifies new effectors of FOXM1 involved in breast cancer cell migration.

Authors:  Xiaojuan Ye; Yi Zhang; Bin He; Yuesheng Meng; Yandong Li; Yong Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.